Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours - Rocket Pharmaceuticals (NASDAQ:RCKT)

Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours - Rocket Pharmaceuticals (NASDAQ:RCKT)

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a firm focused on developing cardiovascular gene therapy, announced a strategic corporate reorganization to extend its runway. The restructuring and reprioritization initiative focuses Rocket’s resources on the adeno-associated virus (AAV) cardiovascular platform, comprised of clinical programs in Danon disease, PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM), and BAG3-associated dilated cardi…

Rocket Pharmaceuticals to cut 30% of workforce

Rocket Pharmaceuticals Inc. announced a “strategic corporate reorganization” July 24 that will result in a workforce reduction of approximately 30%.  That equates to 80 positions eliminated between Oct. 23 and Dec. 31 of this year, according to a Worker Adjustment and Retraining Notification (WARN) filing with the state Department of Labor and Workforce Development.  The Cranbury-based biotechnology company also said it will initiate a “pipeline…